High prevalence of secondary hypertension and insulin resistance in patients with refractory hypertension

Blood Pressure

Volumn 12, Issue 3, 2003, Pages 149-154

  Martell, Nieves ^a   Rodriguez Cerrillo, Matilde ^a   Grobbee, D E ^b   López Eady, M Dolores ^a   Fernández Pinilla, Carmen ^a   Avila, Mario ^a   Fernandez Cruz, Arturo ^a   Luque, Manuel ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Hyperaldosteronism; Insulin resistance; Pheochromocytoma; Refractory hypertension; Secondary hypertension; White coat effect

Indexed keywords

ANTIHYPERTENSIVE AGENT; DIURETIC AGENT; GLUCOSE; INSULIN; SPIRONOLACTONE;

ADULT; AMBULATORY MONITORING; ARTICLE; BLOOD PRESSURE MONITORING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG WITHDRAWAL; FEMALE; HOSPITALIZATION; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; HYPOKALEMIA; INSULIN RESISTANCE; KIDNEY ARTERY STENOSIS; MALE; ORAL GLUCOSE TOLERANCE TEST; PATIENT REFERRAL; PHEOCHROMOCYTOMA; PREVALENCE; PRIORITY JOURNAL; WHITE COAT HYPERTENSION;

EID: 0038107487     PISSN: 08037051     EISSN: None     Source Type: Journal    
DOI: 10.1080/08037050310009950     Document Type: Article

References (39)

1. Sixth report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. Arch Intern Med 1997; 157: 2413-45.
2. Alderman M, Budner N, Cohen H, Lamport B, Lock W. Prevalence of drug resistant hypertension. Hypertension 1988; Suppl II: 71-5.
3. Setaro JF, Black HR. Refractory hypertension. N Eng J Med 1992; 157: 543-6.
4. Swales JD, Bing RF, Heagerty AM, Pohl JE, Russel GI, Thurston H. Treatment of refractory hypertension. Lancet 1982; 1: 894-6.
5. Cuspidi C, Macca G, Sampieri L, et al. High prevalence of cardiac and extracardiac target organ damage in refractory hypertension. J Hypertens 2001; 19: 2063-70.
6. Modan M, Almug S, Fuchs Z, Chetrit A, Lusky A, Halkin H. Obesity, glucose intolerance, hyperinsulinemia and response to antihypertensive drugs. Hypertension 1991; 17: 565-73.
7. De Fronzo RA, Ferrannini E. Insulin resistance: a multi-faceted syndrome responsible for NIDDM, obesity, hypertension, dislipemia and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173-94.
8. Laakso M. How good marker is insulin level for insulin resistance? Am J Epidermol 1993; 137: 959-65.
9. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RL. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-19.
10. Haffner SM, Miettinen H, Stern MP. The homeostasis Model in the San Antonio Heart Study. Diabetes Care 1997; 20: 1087-92.
11. Yakovlevitch M, Black H. Resistant hypertension in a tertiary care clinic. Arch Inter Med 1991; 151: 1786-92.
12. Isaksson H, Danielsson M, Rosenhamer G. Characteristics of patients resistant to antihypertensive drug therapy. J Intern Med 1991; 229: 421-6.
13. Ganguly A. Primary aldosteronism. N Eng J Med 1998; 339: 1828-34.
14. Gordon RD, Stowasser M, Tunny TJ, Klemm SA, Rutherford JC. High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 1994; 21: 315-18.
15. Gordon RD, Ziezac MD, Tunny TJ, Stowasser M, Klemm SA. Evidence that primary aldosteronism may be not be uncommon: 12% incidence among antihypertensive drug trial volunteers. Clin Exp Pharmacol Physiol 1993; 20: 296-98.
16. Lim PO, Dow E, Brennan G, Jung RT, MacDonald TM. High prevalence of primary aldosteronism in the Tayside hypertension clinic population. J Hum Hypertens 2000; 14: 311-15.
17. Bravo E, Tarazi R, Dustan H. The changing clinical spectrum of primary aldosteronism. Am J Med 1983; 74: 641-50.
18. McKenna TJ, Sequeira SJ, Heffernan A, Chambers J, Cunningham S. Diagnosis under random condition of all disorders of renin-angiotensin-aldosterone axis, including primary hyperaldosteronism. J Endocrinol Metab 1991; 73: 952-57.
19. Ferrannini E, Mari A. How to measure insulin sensitivity. J Hypertens 1998; 16: 895-906.
20. Ferrannini E, Haffner SM, Mitchell BD, Stern MP. Hyperinsulinemia: the key feature of a cardiovascular and metabolic syndrome. Diabetologia 1991; 34: 416-22.
21. Rosmond R, Björntorp P. Blood pressure in relation to obesity, insulin and hypothalamic-pituitary adrenal axis in Swedish men. J Hypertens 1998; 16: 1721-1726.
22. Anderson RL, Hamman RF, Savage PJ, et al. for the Insulin Resistance Atherosclerosis Study. Explanation of simple insulin sensitivity measures derived from frequently sampled intravenous glucose tolerance (FSIGT)test: The insulin Resistance Atherosclerosis Study. Am J Epidemiol 1995; 142: 724-32.
23. Saad MF, Anderson RL, Laws A, et al. The Insulin Resistance Atherosclerosis Study Group: a comparison between the minimal model and the glucose clamp in the assessment of insulin sensitivity across the spectrum of glucose tolerance. Diabetes 1994; 43: 1114-21.
24. Hollenbeck CB, Chen N, Chen YDI, Reaven GM. Relationship between the plasma insulin response to oral glucose and insulin stimulated glucose utilization in normal subjects. Diabetes 1984; 33: 460-3.
25. Bonora E, Formentini G, Calcaterra F, et al. HOMA-estimated insulin Resistance is a independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study. Diabetes Care 2002; 25: 1135-41.
26. Hanley AJ, Williams K, Stern MP, Haffner SM. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: The San Antonio Heart Study. Diabetes Care 2002; 25: 1177-84.
27. Dorella M, Giusto M, Da Tos V, Campagnolo M, Palatini P. Improvement of insulin sensitivity by metformin treatment does not lower blood pressure of nonobese insulin resistant hypertensive patients with normal glucose tolerance. J Clin Endocrinol Metab 1996; 81: 1568-74.
28. Endre T, Mattiasson I, Berglund G, Hulthén UL. Insulin and renal sodium retention in hypertensive-prone men. Hypertension 1994; 23: 313-19.
29. + countertransport activity in hypertensive non-insulin dependent diabetic patients: role of insulin resistance and antihypertensive treatment. Metabolism 1997; 46: 1316-23.
30. Banskota NK, Taub R, Zellner K. Characterization of induction of protooncogen c-myc and cellular growth in human vascular smooth muscle cells by insulin and IGF-1. Diabetes 1989; 38: 123-9.
31. Landin K, Tengborn L, Smith V. Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors. J Intern Med 1991; 229: 181-7.
32. Giugliano D, De Rosa N, Di Maro G, Marfella R. Metformin improves glucose lipid metabolism and reduces blood pressure in hypertensive, obese women. Diabetes Care 1993; 16: 1387-90.
33. Bhalla RC, Toth KF, Tan E, Bhatty RA, Mathias E, Sharma RV. Vascular effects of metformin. Possible mechanisms for its antihypertensive action in the spontaneously hypertensive rat. Am J Hypertens 1996; 9: 570-6.
34. Morgan D, Ray CA, Balon TW, Mark AL. Metformin increases insulin sensitivity and lowers arterial pressure in spontaneously hypertensive rats. Hypertension 1992; 20: 421.
35. Verma S, Bhanot S, Mcneill J. antihypertensive effects of metformin in fructose-fed hyperinsulinemic, hypertensive rats. J Pharmacol Exp Ther 1994; 271: 1334-7.
36. Semplicini A, Del Prato S, Giusto M, et al.. Short term effects of metformin on insulin sensitivity and sodium homeostasis in essential hypertensives. J Hypertens 1993; 11: 276-7.
37. Snorgaard O, Kober L, Carlsen J. The effect of metformin on blood pressure and metabolism in nondiabetic hypertensive patients. J Intern Med 1997; 242: 407-12.
38. Pollare T, Lithell H, Berne C. Insulin resistance is a characteristic feature of primary hypertension independent of obesity. Metabolism 1990; 39: 167-74.
39. Facchini F, Chen YDI, Clinkingbead C, Jeppesen J, Reaven GM. Insulin resistance, hyperinsulinemia and dislipemia in nonobese individuals with a family history of hypertension. Am J Hypertens 1992; 5: 694-99.